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Projecting the United States ESRD population: Issues re-
garding treatment of patients with ESRD. In 2001, there
were 406,081 patients who received treatment for end-
stage renal disease (ESRD), increasing by 4.2% since 2000.
The number of patients with ESRD has grown consistently
over the past decade, with the greatest rate of growth oc-
curring among patients older than 75 years of age, and
patients with comorbidities such as diabetes mellitus and hy-
pertension. Current projections indicate that the population of
patients with ESRD may reach more than 2 million by 2030.
The overall mortality rate has fallen by 10% since 1988, with
the greatest decline among patients incident to dialysis, and an
increase among patients receiving dialysis for greater than five
years. While the rate of hospitalization for ESRD patients has
remained relatively constant, recent improvements in mortality
are temporally associated with a greater proportion of patients
achieving adequate benchmarks of care in dialytic processes,
such as anemia correction and dose of dialysis. The ESRD pro-
gram consumes 6.4% of the Medicare budget. On a per-patient
per month basis, Medicare costs have risen between 1991 and
2001. While payments fell slightly during 1998 and 1999 because
of changes in Medicare policies, more recent years have seen
an upswing in total expenditures, presumably related to use
of injectables not included in the composite rate. Continued
growth in the number of new patients reaching ESRD, as well
as improved mortality rates of ESRD patients, are both con-
tributing to the current rise and projected epidemic of ESRD
over the next 25 years. The current public health strategy of
identification of patients with early kidney disease to slow their
progression to ESRD, in addition to aggressive treatment strate-
gies to minimize the morbidity and mortality of patients with
ESRD, is essential toward affecting the growth and health of this
population.
THE EPIDEMIC OF ESRD
During the year 2001, 406,081 patients received treat-
ment for end-stage renal disease (ESRD). Over 96,000
new patients began treatment that year, representing a
4.2% increase since 2000 [1]. The ESRD population has
grown consistently over the past decade (Fig. 1) due to
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both an increase in incidence and a decline in mortal-
ity rate. While this growth has occurred in all demo-
graphic groups, the rate of growth among elderly patients
(older than 75 years of age) has been the greatest and is
most noteworthy (Fig. 2). Moreover, the trend for growth
among the proportion of patients with comorbidities such
as diabetes mellitus and hypertension may be related to
the increase in ESRD incidence rates of elderly patients
(Fig. 3). This disproportionate growth among older pa-
tients and those with certain comorbidities has led to an
increase in the median age of the prevalent population,
from 51 to 58 years since 1978, with a similar increase in
the proportion of patients with diabetes mellitus.
The overall mortality rate for dialysis patients has de-
clined by 10% since 1988. This decline was seen only in
patients who received dialysis for less than two years, and
for those on dialysis for two to five years. In contrast, the
mortality rate for patients receiving dialysis for greater
than five years has recently increased (Fig. 4). Given that
a greater proportion of patients are surviving five years
after starting dialysis, the lack of continued improvement
in survival beyond five years is not easily explained. In
spite of some improvement in survival in the early years
on dialysis, it is noteworthy that the mortality risk for a
patient with ESRD remains strikingly elevated compared
to age-, gender-, and race-matched control patients with-
out kidney disease [2]. For example, a 50-year-old white
male without ESRD can expect to live an additional 28.0
years, while a similar patient with ESRD can expect to
live only 5.3 years.
The same consideration should be given to patients
with chronic kidney disease (CKD) who do not yet re-
quire renal replacement therapy. Based on the National
Kidney Foundation’s classification system for CKD, ap-
proximately eight million people in the United States
have an estimated glomerular filtration rate (GFR) of
less than 60 mL/min/1.73 m2 [3]. Similar to the ESRD
population, the proportion of the CKD population with
diabetes mellitus is increasing [1]. While the mortality
rates for patients with CKD may have slightly declined
in recent years [1], it is noteworthy that CKD patients
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Fig. 1. Number of patients incident and prevalent to end-stage renal
disease (ESRD) by renal replacement therapy modality (USRDS 2003
Annual Data Report).
are still five to 10 times more likely to die than to reach
ESRD [3]. The strikingly disproportionate rate of sudden
cardiac death in this population is further supported by
the increased risk for the development of new cardiovas-
cular disease. Patients with CKD who have no previous
need for cardiovascular care have a 60% to 70% greater
risk for requiring initial and subsequent care for cardio-
vascular disease (i.e., development of incident cardiovas-
cular disease) than their non-CKD counterparts during
the subsequent year [1].
It is projected that the current growth in the size of
population of patients with diabetes mellitus and CKD
will lead to a steady increase in the number of ESRD pa-
tients, so that by the year 2030, 2.24 million patients will
require some form of renal replacement therapy [1]. This
means that an enormous number of CKD and ESRD pa-
tients will be at significant risk for cardiovascular disease,
and with strikingly high mortality rates compared with
patients without kidney disease. Consequently, it will be
essential to plan recruitment of the necessary resources
for the growth in size of these populations, as well as for
the issues of aging and worsening comorbidities.
MORBIDITY AND MORTALITY ASSOCIATED
WITH ESRD
Overall, there have been significant improvements in
both morbidity and mortality among patients with ESRD
over the last decade [1]. Among these patients, admis-
sions for vascular access fell by 24%, but admissions
related to circulatory and respiratory diseases grew by
13.5% and 11.5%, respectively. This resulted in a rela-
tively stable all-cause hospitalization rate for prevalent
dialysis patients, decreasing by barely 1% between 1993
and 2001. Interestingly, however, this was accompanied
by a 15% to 20% reduction in total hospital days per year.
On the other hand, the mortality rate has decreased by
10% since 1980, clearly seen among patients incident to
dialysis. However, the change in mortality has been quite
different among different patient groups. Those with less
than two years on dialysis, as well as those who were
on dialysis for two to five years experienced a 22% and
15% decline in mortality rates, respectively. By contrast,
those who had been on dialysis for more then five years
had a 7% increase in mortality rate. The increase in mor-
tality among patients with a greater dialysis vintage en-
tails greater clinical and research focus on complications
that occur over time, such as accelerated atherosclerosis,
hypertension, hypervolemia, lipid abnormalities, insulin
resistance, disordered mineral metabolism, hyperhomo-
cysteinemia, and/or physical inactivity seen among pa-
tients with ESRD [4–12].
Factors that have been linked to increasing mortality
in large observational studies include demographic and
clinical characteristics that may or may not be modifi-
able. Examples of these include low serum albumin lev-
els, increasing age, female gender, and white race [13,
14, 15]. Moreover, dialysis-related factors have also been
linked to mortality. These include issues that have led to
the development of various National Kidney Foundation
(NKF) clinical practice guidelines (Dialysis Outcomes
Quality Initiative, or DOQI) including dialysis dose [as
measured by either urea reduction ratio (URR) or Kt/V],
anemia, and calcium and phosphorus metabolism. For
instance, numerous observational studies have demon-
strated an association between increased dose of dialysis
and a decreased mortality rate [15–24]. Based on these
findings, the National Kidney Foundation’s Dialysis Out-
comes Quality Initiative Guidelines recommend a min-
imum delivered dose of dialysis of a Kt/V of 1.2 or a
URR of 65% [25]. Similarly, increased hematocrit and
hemoglobin levels have been associated with improve-
ments in muscle strength and function [26], cognitive and
brain electrophysiologic function [27], cardiac function
[28–33], sexual function [34], quality of life [35], and sur-
vival [36, 37]. The exception was the result of a clini-
cal trial by Besarab et al [38] that randomized patients
with ESRD and cardiac disease to either a hematocrit
of 30% or 42%. This trial failed to demonstrate a bene-
fit for normalizing the hematocrit. Therefore, the current
NKF-DOQI guidelines recommended that the target for
anemia correction is a hematocrit of 33% to 36%, or
hemoglobin of 11 to 12 g/dL.
It is interesting that in studies utilizing two large
datasets representative of the United States dialysis pop-
ulation, the recent decline in mortality rate was accom-
panied by a simultaneous improvement in the proportion
of patients reaching the goals for dialysis dose and hemat-
ocrit level [39, 40]. However, in spite of the decline in mor-
tality rate, the relative proportions of deaths attributed
to cardiovascular, infectious, and other causes of death
have not changed substantively [1].
Similar relationships between serum calcium, serum
phosphorus, and the calcium-phosphorus product and
Szczech and Lazar: Projecting the U.S. ESRD population S-5
81 85 8783 89 9391 9795 99 01
0
10
20
30
40
N
um
be
r o
f p
at
ie
nt
s,
 in
 th
ou
sa
nd
s
0-19
20-44
45-64
65-74
75+
81 85 8783 89 9391 9795 99 01
0
400
800
1200
1600
R
at
e 
pe
r m
illi
on
 p
op
ul
at
io
n
0-19
20-44
45-64
65-74
75+
All
Fig. 2. Number and rates of patients incident
to end-stage renal disease (ESRD) by age
(USRDS 2003 Annual Data Report).
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Fig. 3. Number and rates of patients incident
to end-stage renal disease (ESRD) by pri-
mary diagnosis (USRDS 2003 Annual Data
Report).
mortality have also been examined. Recommendations
to maintain serum calcium within normal range (e.g.,
8.4 to 9.5 mg/dL) are supported by observational stud-
ies that showed an association between hypocalcemia
and increased mortality [41–44]. Moreover, recommen-
dations to maintain the serum phosphorus between 3.5
and 5.5 mg/dL and calcium-phosphorous product below
55 mg/dL2 are supported by similar observational data
that revealed an 11% increase in mortality with each
10 mg/dL2 increase in the product [45]. The impact of
these guidelines on subsequent trends in morbidity and
mortality will have to be reassessed in subsequent years.
IMPACT OF ESRD POPULATION GROWTH ON
HEALTH CARE COSTS
Strategies for caring for patients with ESRD must take
into account the needs of the current patient population,
and simultaneously plan for the future growth of this
population. These include the provision of dialysis and
dialysis related-services, creation and maintenance of
vascular access, kidney transplantation, the cost of med-
ications, and care for other comorbidities of this popula-
tion through both inpatient and outpatient services.
On a per-patient basis, Medicare costs have risen each
year between 1991 and 2001. During 1998 and 1999, how-
ever, the rate of growth for payments fell slightly at only
1.8% and 4.2%, presumably because of changes in Medi-
care policies for home health and skilled nursing facili-
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Fig. 4. Mortality rates (adjusted) for patients receiving dialysis, by vin-
tage (USRDS 2003 Annual Data Report).
ties. Total Medicare expenditures for the remaining years,
however, have continued to increase, concomitant with
the rise in the ESRD population, with increases in total
expenditures of 8.1% and 11.5% in the last two years. The
increases appear to be related to services not currently in-
cluded in the composite rate. Examining costs per-patient
per month demonstrates increasing billing for injectables
such as intravenous (IV) vitamin D, IV iron, and erythro-
poietin (Fig. 5). Expenditures for IV iron increased by
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Fig. 5. Per-patient per month costs for clinical services for prevalent
dialysis patients (USRDS 2003 Annual Data Report).
almost 16% in 2001, and expenditures for IV vitamin D
increased by 41% and 19% in 2000 and 2001 as a result
of billing for Zemplar rather than Calcijex.
The changing demographics of the ESRD population
have and will likely continue to affect Medicare expendi-
tures. The aging of the ESRD population, and the greater
number of patients with diabetes mellitus, are consuming
an increasing part of the ESRD program expenditures.
The ESRD program currently consumes 6.4% of the en-
tire Medicare budget of $242 billion. This is a 33% in-
crease over the last 11 years. Given the changes to the
ESRD population and projected trends for growth, the
projected costs of this program for third party payers over
the next decades are daunting.
These projections include Medicare costs but do not
reflect the out of pocket costs for patients. Noteworthy is
the fact that the increase in cost of injectables occurred
temporally with the NKF guidelines for benchmarks of
dialytic care [25]. If this was true, then a similar relation-
ship between increased use of oral medications and these
guidelines may have occurred, but was not reflected in
the summary estimates or projections. These costs may
be borne directly by the patients or other third party pay-
ers and may contribute to the increasing costs paid for
outside the Medicare program.
CONCLUSION
The recent increase in the number of ESRD patients
and the decline in mortality rate among these patients
have both contributed to a projected epidemic of ESRD
over the next 25 years. Healthy People 2010 are a set of na-
tional health objectives designed to address preventable
threats to health and to establish national goals to reduce
these threats [46]. Given the demonstrated current in-
crease in ESRD population and the cost of this program
to Medicare, strategies to reduce the ESRD burden are
timely and appropriate.
In spite of tremendous advances in understanding the
factors that contribute to the increased morbidity and
mortality of patients with ESRD, the fact remains that
the risk of cardiovascular disease is greater than that in
the general population without kidney disease. Hence,
further research is essential in order to understand the
underlying mechanisms for the enormous burden of
cardiovascular disease and accelerated atherosclerosis.
Moreover, research should also focus on identifying mod-
ifiable risk factors that negatively impact outcomes expe-
rienced by patients with ESRD. Furthermore, it will be
imperative to focus on identifying patients with early kid-
ney disease and to implement therapeutic strategies in an
attempt to slow their progression to ESRD. By employ-
ing this two-pronged approach, we may able to both slow
the growth of the ESRD population and simultaneously
decrease their morbidity and mortality.
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